Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02173210 · ClinicalTrials.gov registry record
Precision Medicine for Preterm Birth
A clinical trial, sponsored by University of Pennsylvania.
- Completed
- Registry status
- 380
- Enrollment target
NCT02173210: Completed study, sponsored by University of Pennsylvania.
NCT02173210 is a clinical trial that has completed, run by University of Pennsylvania. The registered enrollment target is 380 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02173210 has completed, sponsored by University of Pennsylvania.
- COMPLETED
- Registry status
- 380 participants
- Enrollment target
Study Summary
This project is examining genetic and metabolic markers for the use of 17 hydroxyprogesterone caproate (17OHPC) in pregnant women with a history of preterm birth (PTB). 17OHPC has been associated with a 30-35% reduction in repeat PTB in women carrying a singleton gestation. However, it is not well known why it works for some women but not for others. There are limited available interventions for the prevention of recurrent PTB. This study will enroll 150 women at risk for PTB and eligible to receive 17OHPC, and expect that 80% will use 17OHPC and 20% will decline use. We will obtain blood samples and samples of cervical cells and cervical vaginal fluid. The objective of the study is to identify genetic, microbial and molecular markers that help to identify which women at risk for recurrent preterm birth will respond to 17OHPC and which women will not. The ultimate goal is to develop a personalized screening test based on these markers.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 380 participants |
| Start Date | 2014-06-25 |
| Est. Completion | 2017-12-27 |
What the finished NCT02173210 record still lists
NCT02173210 is an observational study that tracks outcomes without assigning an intervention. The registered 380 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT02173210 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02173210 about?
NCT02173210 is a clinical study titled "Precision Medicine for Preterm Birth". This project is examining genetic and metabolic markers for the use of 17 hydroxyprogesterone caproate (17OHPC) in pregnant women with a history of preterm birth (PTB). 17OHPC has been associated with a 30-35% reduction in repeat PTB in women carrying a singleton gestation. However, it is not well k...
What is the current status of trial NCT02173210?
This trial is currently completed. The enrollment target is 380 participants. The study started on 2014-06-25. Estimated completion is 2017-12-27.
Who is sponsoring clinical trial NCT02173210?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04560673 · 380 participants · Phase 2
Duloxetine and Neurofeedback Training for the Treatment of Chemotherapy Induced Peripheral Neuropathy
- NCT04777357 · 380 participants · Phase 3
A Study to Assess Change in Disease Activity and Adverse Events (AEs) With Cariprazine in the Treatment of Depressive Episodes in Pediatric Participants Participants (10 to 17 Years of Age) With Bipolar I Disorder.
- NCT04821154 · 380 participants
Persona Revision Knee System Outcomes
- NCT05102019 · 380 participants · NA
Efficacy of the COronary SInus Reducer in Patients With Refractory Angina II
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI